Cytomx Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cytomx Therapeutics, Inc. on January 25, 2019. The report details Item 5.02 regarding the Compensation Committee's approval of annual base salaries for 2019 and cash performance bonuses for 2018 for the company's principal executive officers and named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes and Compensation Details
On January 25, 2019, the Board approved the following compensation adjustments:
| Officer | Position | 2019 Salary Increase (%) | 2019 Salary Increase ($) | 2019 Base Salary ($) | 2018 Cash Bonus ($) |
|---|---|---|---|---|---|
| Sean A. McCarthy | President, CEO, Chairman | 4.5% | $25,000 | $575,000 | $412,500 |
| Debanjan Ray | Chief Financial Officer | 4.0% | $15,750 | $409,500 | $196,875 |
| Rachel W. Humphrey | Chief Medical Officer | 4.0% | $17,617 | $458,065 | $220,224 |
| W. Michael Kavanaugh | Chief Scientific Officer | 4.0% | $17,094 | $444,451 | $213,678 |
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items beyond the compensation approvals.
Key Facts for Investor Verification
- Verify the total cash outflow for 2018 performance bonuses totaling approximately $1.04 million.
- Confirm the 2019 base salary increases for the executive team, ranging from 4.0% to 4.5%.
- Note that this filing does not contain operational or financial performance data for the company.